Drug intelligence / Profile preview

IDB-011

Development stage: Phase 1
Lead developer: IDBiologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular

Overview

IDB-011 is an investigational **two-monoclonal-antibody combination** comprising IDB-774 and IDB-898, developed as a medical countermeasure against Rift Valley fever virus infection. The human antibodies bind distinct critical viral residues, directly neutralize Rift Valley fever virus replication, and have been engineered for extended half-life. The components are administered as separate consecutive intramuscular injections. IDB-011 is being evaluated in a randomized, placebo-controlled Phase 1 study in healthy adults for safety, tolerability, pharmacokinetics, and immunogenicity. ([idbiologics.com](https://idbiologics.com/pipeline))

Brand names: IDB-011IDB011IDB 011
Other names: IDB-774 + IDB-898

Beyond the preview

Go deeper on IDB-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDB-011.

Explore the full profile